NASDAQ:NVAX Novavax (NVAX) Stock Price, News & Analysis $9.98 -0.22 (-2.16%) Closing price 11/11/2026 04:00 PM EasternExtended Trading$9.95 -0.03 (-0.30%) As of 04:25 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Novavax Stock (NASDAQ:NVAX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Novavax alerts:Sign Up Key Stats Today's Range$9.90▼$10.3650-Day Range$9.23▼$12.8252-Week Range$6.20▼$13.39Volume5.89 million shsAverage Volume6.64 million shsMarket Capitalization$1.65 billionP/E RatioN/ADividend YieldN/APrice Target$12.33Consensus RatingHold Company Overview Novavax, Inc. is a biotechnology company focused on developing vaccines for infectious diseases. Its technology combines recombinant protein-based vaccine antigens with Matrix-M, a saponin-based adjuvant designed to strengthen the immune response. The company’s best-known product is Nuvaxovid, a protein-based COVID-19 vaccine authorized in the United States and other markets. Novavax also develops additional vaccine candidates, including a combination COVID-19 and influenza vaccine. Founded in 1987 and headquartered in Gaithersburg, Maryland, Novavax serves international markets through regulatory approvals and commercial partnerships. In 2024, it entered a licensing and collaboration agreement with Sanofi covering its COVID-19 vaccine and combination-vaccine development.AI Generated. May Contain Errors. Read More Novavax Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreNVAX MarketRank™: 2.0498687664 of 5 starsNovavax scored higher than 41% of companies evaluated by MarketBeat, and ranked 706th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingNovavax has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on no strong buy ratings, 5 buy ratings, 2 hold ratings, and 3 sell ratings.Upside PotentialNovavax has a consensus price target of $12.33, representing about 23.6% upside from its current price of $9.98.Amount of Analyst CoverageNovavax has only been the subject of 4 research reports in the past 90 days.Read more about Novavax's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Novavax are expected to decrease in the coming year, from ($0.02) to ($0.27) per share. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted28.54% of the float of Novavax has been sold short.Short Interest Ratio / Days to CoverNovavax has a short interest ratio ("days to cover") of 7.61.Change versus previous monthShort interest in Novavax has recently decreased by 2.15%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNovavax does not currently pay a dividend.Dividend GrowthNovavax does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.36 News SentimentNovavax has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 34 news articles for Novavax this week, compared to 8 articles on an average week.Search InterestOnly 25 people have searched for NVAX on MarketBeat in the last 30 days. This is a decrease of -49% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Novavax to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Novavax insiders have not sold or bought any company stock.Percentage Held by Insiders1.60% of the stock of Novavax is held by insiders.Percentage Held by Institutions53.04% of the stock of Novavax is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Novavax's insider trading history. Receive NVAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novavax and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NVAX Stock News HeadlinesNovavax to Participate in Jefferies London Healthcare ConferenceNovember 11 at 8:00 PM | finance.yahoo.comNovavax to Participate in Jefferies London Healthcare ConferenceNovember 11 at 5:00 PM | prnewswire.comWatch This NowJensen Huang, the man who launched the AI boom, just called what Elon Musk is chasing "the final frontier of AI." Musk's track record includes PayPal, Tesla and SpaceX. Tim Bohen has put the details of what he calls Musk's Mission X into a brand-new masterclass, free to watch with no credit card required. Viewers also receive a free ticker tied to Mission X. | StocksToTrade (Ad)Novavax (NVAX) stock trades up, here is whyNovember 10 at 9:42 AM | finance.yahoo.comNovavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on ItNovember 10 at 9:42 AM | finance.yahoo.comNVAX Q3 2026 deep dive: Sanofi milestone and cost controls shape outlookNovember 10 at 9:42 AM | finance.yahoo.comNovavax (NASDAQ:NVAX) Upgraded at Wall Street ZenNovember 10 at 2:18 AM | americanbankingnews.comNovavax, Inc. 2026 Q3 - Results - Earnings Call PresentationNovember 9 at 12:07 AM | seekingalpha.comSee More Headlines NVAX Stock Analysis - Frequently Asked Questions How have NVAX shares performed this year? Novavax's stock was trading at $6.72 at the beginning of 2026. Since then, NVAX stock has increased by 48.5% and is now trading at $9.98. How were Novavax's earnings last quarter? Novavax, Inc. (NASDAQ:NVAX) released its quarterly earnings data on Thursday, November, 5th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.16. The business's revenue for the quarter was down 3.0% compared to the same quarter last year. Read the conference call transcript. When did Novavax's stock split? Novavax shares reverse split on Friday, May 10th 2019.The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 9th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are Novavax's major shareholders? Novavax's top institutional shareholders include Shah Capital Management (7.38%), TSP Capital Management Group LLC (0.87%), Voya Investment Management LLC (0.18%) and Russell Investments Group Ltd. (0.06%). Insiders that own company stock include James F Young, Filip Dubovsky and Rachel K King. View institutional ownership trends. How do I buy shares of Novavax? Shares of NVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Novavax own? Based on aggregate information from My MarketBeat watchlists, some other companies that Novavax investors own include Moderna (MRNA), Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), NIO (NIO), PayPal (PYPL) and Alibaba Group (BABA). Company Calendar Last Earnings11/05/2026Today11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (8m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 NVAX's financial health is in the Green zone, according to TradeSmith. NVAX has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:NVAX CIK1000694 Webwww.novavax.com Phone(240) 268-2000Fax240-268-2100Employees749Year Founded1987Price Target and Rating Average Price Target for Novavax$12.33 High Price Target$19.00 Low Price Target$6.00 Potential Upside/Downside+23.6%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($0.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$440.30 million Net Margins-18.64% Pretax Margin-17.47% Return on Equity-14.82% Return on Assets-7.55% Debt Debt-to-Equity RatioN/A Current Ratio2.15 Quick Ratio2.09 Sales & Book Value Annual Sales$1.12 billion Price / Sales1.47 Cash Flow$3.43 per share Price / Cash Flow2.91 Book Value($1.31) per share Price / Book-7.62Miscellaneous Outstanding Shares165,010,000Free Float162,369,000Market Cap$1.65 billion OptionableOptionable Beta2.65 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:NVAX) was last updated on 11/11/2026 by MarketBeat.com Staff. From Our PartnersWatch This NowJensen Huang, the man who launched the AI boom, just called what Elon Musk is chasing "the final frontier of A...StocksToTrade | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | SponsoredThis 10.3% war bond closed once. It's finally open again.Todd Phillips has spent 30 years studying safe-money income. His test for real retirement income: can it promi...Eagle Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novavax, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Novavax With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
